肾功能与缺血性心衰患者冠脉搭桥手术的关系
该研究基于STICH试验1209例缺血性心衰患者,评估慢性肾病对10年死亡和心血管结局及CABG疗效的影响。结果显示eGFR与死亡、心血管死亡或再住院风险负相关,轻中度慢性肾病不影响CABG的长期治疗效果。
要点
- 慢性肾病是缺血性心衰患者死亡的独立危险因素
- 轻中度慢性肾病不影响CABG的长期治疗效果
- eGFR与死亡、心血管死亡或再住院风险负相关
核心结论
- 慢性肾病是缺血性心衰患者无论是否接受CABG的独立死亡危险因素。
- 轻中度慢性肾病似乎不影响CABG的长期治疗效果。
研究设计与样本
- 基于Surgical Treatment for IsChemic Heart failure试验的1209例随机接受药物治疗或冠状动脉旁路移植术的患者。
- 计算基线估计肾小球滤过率(CKD-EPI公式,慢性肾病1-5期)并评估其对结局的影响。
主要发现
- 慢性肾病3-5期患者比1-2期患者年龄更大(66-71岁 vs 54-59岁)且合并症更多。
- 多变量模型显示eGFR与死亡、心血管死亡或心血管再住院风险呈负相关(均P < .001),但与卒中无关(P = .697)。
- 4期和5期因患者数不足(N = 28)数据不确定。
- eGFR与CABG治疗效果无显著交互作用(死亡P = .25,死亡或心血管再住院P = .54)。
临床怎么用
- 对合并轻中度慢性肾病的缺血性心衰患者,CABG的长期获益不受肾功能显著影响。
- 慢性肾病应作为缺血性心衰患者死亡风险分层的重要因素。
局限性
- 4期和5期慢性肾病患者数量少(N = 28),结果不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic kidney disease is a known risk factor in cardiovascular disease, but its influence on treatment effect of bypass surgery remains unclear. We assessed the influence of chronic kidney disease on 10-year mortality and cardiovascular outcomes in patients with ischemic heart failure treated with medical therapy (medical treatment) with or without coronary artery bypass grafting. METHODS: We calculated the baseline estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration formula, chronic kidney disease stages 1-5) from 1209 patients randomized to medical treatment or coronary artery bypass grafting in the Surgical Treatment for IsChemic Heart failure trial and assessed its effect on outcome. RESULTS: In the overall Surgical Treatment for IsChemic Heart failure cohort, patients with chronic kidney disease stages 3 to 5 were older than those with stages 1 and 2 (66-71 years vs 54-59 years) and had more comorbidities. Multivariable modeling revealed an inverse association between estimated glomerular filtration rate and risk of death, cardiovascular death, or cardiovascular rehospitalization (all P < .001, but not for stroke, P = .697). Baseline characteristics of the 2 treatment arms were equal for each chronic kidney disease stage. There were significant improvements in death or cardiovascular rehospitalization with coronary artery bypass grafting (stage 1: hazard ratio, 0.71; confidence interval, 0.53-0.96, P = .02; stage 2: hazard ratio, 0.71; confidence interval, 0.59-0.84, P < .0001; stage 3: hazard ratio, 0.76; confidence interval, 0.53-0.96, P = .03). These data were inconclusive in stages 4 and 5 for insufficient patient numbers (N = 28). There was no significant interaction of estimated glomerular filtration rate with the treatment effect of coronary artery bypass grafting (P = .25 for death and P = .54 for death or cardiovascular rehospitalization). CONCLUSIONS: Chronic kidney disease is an independent risk factor for mortality in patients with ischemic heart failure with or without coronary artery bypass grafting. However, mild to moderate chronic kidney disease does not appear to influence long-term treatment effects of coronary artery bypass grafting.
引用
- Doenst T, Haddad H, Stebbins A, et al. Renal function and coronary bypass surgery in patients with ischemic heart failure. J Thorac Cardiovasc Surg. 2020. PMID: 32386761. doi:10.1016/j.jtcvs.2020.02.136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。